Pipeline

At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.

Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.

DISEASE STATES

CHRONIC HEPATITIS B VIRUS INFECTION
Phase 1

PAPD5/7 Inhibitor (GSK3965193)*

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Go to ResourceOpen link icon
CHRONIC HEPATITIS B VIRUS INFECTION
Phase 2

HBV Antisense Oligonucleotide (bepirovirsen)†

Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)

Go to ResourceOpen link icon

Therapeutic hepatitis B vaccine candidate GSK3528869A†

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Go to ResourceOpen link icon

Therapeutic hepatitis B (CHBV ASO Combo) vaccine candidate GSK4388067A† and HBV Antisense Oligonucleotide (bepirovirsen)†

A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Go to ResourceOpen link icon

HBV Antisense Oligonucleotide (bepirovirsen)† in sequential assignment with daplusiran/tomligisiran† 

A Study of Sequential Therapy with Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living with Chronic Hepatitis B (B-UNITED)

Go to ResourceOpen link icon

HBV Antisense Oligonucleotide (bepirovirsen)†

Study of Bepirovirsen in Participants Living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Go to ResourceOpen link icon
CHRONIC HEPATITIS B VIRUS INFECTION
Phase 3

HBV Antisense Oligonucleotide (bepirovirsen)†

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Go to ResourceOpen link icon

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Go to ResourceOpen link icon
NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase 2

HSD17B13 Small Interfering RNA†

Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

Go to ResourceOpen link icon

Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH (SKYLINE)

Go to ResourceOpen link icon
CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS
Phase 3

Ileal Bile Acid Transporter (IBAT) Inhibitor (Linerixibat)

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Go to ResourceOpen link icon

Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

Go to ResourceOpen link icon
Alcohol-Related Liver Disease (ALD)
Phase 2

HSD17B13 Small Interfering RNA†

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared with Placebo in Adult Participants Aged 18 to 65 Years with Alcohol-related Liver Disease (STARLIGHT)

Go to ResourceOpen link icon

0 results - Use filter to search Pipeline

Disclaimer

This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.

Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.

 

Footnotes

*in Phase 1/2 Study.

†In-licence or other alliance relationship with third party